Evidence map›Paper›PMID 41877067›Full record

ArticleBMC infectious diseases2026

Molecular network characteristics and transmissible drug resistance of HIV-1 CRF55_01B in Yunnan Province.

Yuan Li, Jincheng Lou, Jianjian Li, Yuanlu Shu, Tianshu Li, Yunfei Lao, Xingqi Dong, Jiafa Liu

Abstract read
In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuan LiPublic Health Department, Yunnan Provincial Infectious Disease Hospital, Kunming, Yunnan, 650301, China.
Jincheng LouPublic Health Department, Yunnan Provincial Infectious Disease Hospital, Kunming, Yunnan, 650301, China.
Jianjian LiDepartment of Clinical Laboratory, Yunnan Provincial Hospital of Infectious Diseases, Kunming, Yunnan, 650301, China.
Yuanlu ShuDepartment of Clinical Laboratory, Yunnan Provincial Hospital of Infectious Diseases, Kunming, Yunnan, 650301, China.
Tianshu LiPublic Health Department, Yunnan Provincial Infectious Disease Hospital, Kunming, Yunnan, 650301, China.
Yunfei LaoPublic Health Department, Yunnan Provincial Infectious Disease Hospital, Kunming, Yunnan, 650301, China. laoyunfei@hotmail.com.
Xingqi DongPublic Health Department, Yunnan Provincial Infectious Disease Hospital, Kunming, Yunnan, 650301, China. dongxqdoctor@163.com.
Jiafa LiuPublic Health Department, Yunnan Provincial Infectious Disease Hospital, Kunming, Yunnan, 650301, China. cdyxyljf@sina.com.

Funding

the Major Science and Technology Project of Yunnan Provincial Science and Technology Department No. 202405AJ310002the Yunnan Provincial Department of Science and Technology, Kunming Medical University Joint Special Fund for Applied Basic Research 202201AY070001-208
6 · The paper itself

Abstract

objectiveBy using molecular network technology to analyze the transmission characteristics of the CRF55_01B strain in Yunnan Province, we aimed to identify high-risk transmitters, trace the origin time, location, transmission routes and transmitted drug resistance(TDR) of the virus, and provide a data basis for subsequent surveillance.

methodsDemographic data and laboratory test results were collected from all newly diagnosed and treatment-naïve individuals infected with the CRF55_01B strain in Yunnan Province, from January 2020 to December 2024. The molecular network of the CRF55_01B strain was constructed via the paired gene distance method, with Cytoscape 3.10.1 software employed to visualize and analyze the network. BEAST software was used to construct the MCC tree and estimate posterior probabilities, while SpreaD3 was employed to visualize spatiotemporal diffusion and calculate Bayes factors for transmission path analysis. Drug resistance analysis was conducted via the Stanford HIV Drug Resistance Database (HIVdb).

resultsA total of 68 newly diagnosed and treatment-naïve patients infected with the CRF55_01B strain in Yunnan Province were enrolled. With 0.018 as the optimal genetic distance threshold, a molecular network was constructed, yielding a network access rate of 57.35% (39/68). A total of 14 molecular clusters were formed, most of which consisted of two sequences. Among 68 participants, 8.82% (6/68) had drug-resistant infections, while the drug resistance mutation rate of the tested strains was as high as 98.53% (67/68). Half of the drug-resistant patients (3/6) were incorporated into the molecular network, leading to the formation of a single drug-resistant transmission cluster. Analysis of transmission network signatures (TNSs) identified 7 high-risk transmitters. Bayesian phylogenetic analysis revealed that the most recent common ancestor (tMRCA) of the CRF55_01B strain dated back to 2002.03; the strain entered Qujing City, Yunnan Province via heterosexual transmission in 2005.20, and was simultaneously detected in Pu’er City and Wenshan Prefecture in the same year. In approximately 2006.16, it was first found among the men who have sex with men (MSM) population in Yunnan Province. Since then, it has spread bidirectionally between MSM and heterosexual populations. Multiple transmission patterns were observed, including intra-familial, local, cross-regional, and multi-partner transmission, accompanied by transmitted drug resistance (TDR). Imported cases were mainly from Hubei and Guangdong Provinces, with Honghe Prefecture serving as the primary entry point in Yunnan.

conclusionsThe CRF55_01B strain was introduced into Qujing City, Yunnan Province, via heterosexual contact around 2005.20. Thereafter, the virus exhibited a bidirectional spread​ between MSM and heterosexual populations, demonstrating diverse transmission patterns including intra-familial, local, cross-regional, and multi-partner transmission. Meanwhile, evidence of drug-resistant strain transmission was detected. Molecular transmission network analysis further revealed that over 40% of potential concealed transmission sources remained unincorporated into the network. Based on this, it is recommended to adopt differentiated monitoring strategies, with a focus on strengthening the monitoring of drug-resistant strains in core hub areas and precise interventions for mobile populations. CLINICAL TRIAL: Not applicable.

Indexed as

Drug Resistance, ViralHIV-1HIV InfectionsAdultAnti-HIV AgentsChinaFemaleGenome, ViralGenotypeHumansMaleMiddle AgedMutationPhylogenyAnti-HIV AgentsCRF55_01BHIV-1Molecular transmission network characteristicsTransmitted drug resistance

Identifiers

PMID41877067
PMCPMC13134180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.